WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that it has initiated a Phase 1 clinical trial of TC-5214. Targacept is developing TC-5214 as an augmentation therapy for major depressive disorder (MDD). A Phase 2 clinical proof of concept trial is planned for later in 2008.
